Klotho — the longevity protein and the cognitive aging connection

The naming was deliberate. In Greek mythology, Klotho is the spinner, one of the three Moirai who control destiny and lifespan. Without her spinning, the thread of life does not begin. Kuro-o's observation was that without the gene, life ran through its program far too quickly — as if the mechanism that normally sets the pace of aging had been removed. When the lab subsequently created mice that overexpressed klotho rather than lacking it, those animals lived about thirty percent longer than controls and showed improvements in several age-related measures. The symmetry was striking: delete klotho, animals age prematurely and die young; add klotho, animals live longer. A gene whose expression appeared to directly modulate the pace of aging across multiple organ systems simultaneously.

The biology of klotho has turned out to be considerably more complex than a single lifespan gene, and the complexity is worth understanding because it explains both why klotho is genuinely important and why translating it into a therapeutic is not straightforward.

There are two forms. The membrane-bound form — sometimes called alpha-klotho, or simply klotho, as it was the first discovered — is a single-pass transmembrane protein expressed predominantly in the kidney and in the choroid plexus of the brain. In the kidney, membrane-bound klotho functions as an obligate co-receptor for FGF23, a hormone produced by bone that travels to the kidney and parathyroid gland to regulate phosphate reabsorption and vitamin D metabolism. Without klotho as a co-receptor, FGF23 cannot bind its receptor at sufficient affinity to signal; when the klotho-deficient mouse develops hyperphosphatemia and abnormal vitamin D levels, much of the resulting premature aging phenotype can be partially reproduced simply by feeding mice excessive phosphate or vitamin D, and partially rescued by normalizing those levels. The kidney-bone axis that klotho anchors is not a peripheral metabolic detail — disturbed phosphate metabolism accelerates cardiovascular calcification, bone loss, and kidney disease in ways that mirror what aging does more slowly.

The second form — soluble klotho — is a fragment of the ectodomain of membrane-bound klotho, cleaved by membrane proteases (primarily ADAM10 and ADAM17) and released into the bloodstream. Soluble klotho has different biology from the membrane-bound form. It circulates systemically, at levels that are measurable in the blood and that decline with age in humans in a consistent and well-documented pattern. It appears to have effects on cells that don't express membrane-bound klotho, suggesting it acts as an endocrine signal — a circulating factor that carries information about the organism's metabolic state to distant tissues.

The downstream biology of soluble klotho is still being characterized, and the picture is not simple, but several themes have emerged from consistent enough research to describe with confidence. Klotho has anti-inflammatory effects: it suppresses NF-kB signaling, one of the central inflammatory transcription factor networks, in multiple cell types. It has mitochondrial protective effects, reducing oxidative stress in cells exposed to it. It has anti-apoptotic effects in certain cellular contexts. It appears to modulate Wnt and TGF-beta signaling in ways that affect fibrosis and tissue remodeling. In the kidney, it helps protect tubular epithelial cells from injury-induced senescence and fibrosis. In the vasculature, it appears to have endothelial protective effects. In bone, it modulates FGF23 signaling in ways that affect mineralization. The multiplicity of effects across different organ systems is consistent with a circulating factor that is, in some sense, an organizational signal for systemic tissue health — and with why its loss produces such broad and multisystem accelerated aging.

The cognition connection is where klotho's biology has intersected most provocatively with human aging research. Circulating klotho levels in older adults correlate with cognitive performance in multiple observational studies: people with higher klotho levels score better on tests of executive function, memory, and processing speed, even after controlling for age and other covariates. This correlation could be confounded — healthier people might have higher klotho for reasons that also improve cognition — but the consistency across studies has drawn sustained attention.

The genetic data adds a dimension to this. A common variant in the human klotho gene called KL-VS — named for the amino acid changes it produces in the protein, valine at one position and serine at another — has been studied in the context of both longevity and cognition. The KL-VS variant produces a form of klotho with somewhat different properties than the common form. Heterozygotes for KL-VS — people who carry one copy of the variant and one copy of the common form — appear in several population studies to have modestly better cognitive performance and in some cohorts to have a survival advantage, with a higher frequency among centenarians than in control populations. Homozygosity for KL-VS, by contrast, may be disadvantageous, which is the U-shaped dose-response pattern that sometimes appears in biology when moderate variation is beneficial but extreme variation is not. The genetic association is not uniformly replicated across all populations and cohorts, and the effect sizes are modest, but the pattern has appeared enough times across independent datasets to be taken seriously by researchers in the aging genetics space.

The mouse work on cognition is more direct and more dramatic. Researchers have shown that klotho-deficient mice have significant cognitive deficits — impaired performance in spatial memory and learning tasks — that appear in advance of the general aging phenotype, suggesting the cognitive effects are not simply a downstream consequence of systemic deterioration. When klotho is administered to normal aging mice, it improves cognitive performance. The effect is associated with enhanced synaptic plasticity, particularly in the hippocampus, and appears to involve GluN2B, a subunit of NMDA receptors that is important for synaptic plasticity and learning. Aged mice given klotho show hippocampal NMDA receptor changes that resemble those of younger animals. These are preclinical findings; mouse cognition does not map directly onto human cognitive aging, and extrapolation requires caution. But the mechanistic specificity — a defined receptor and a defined plasticity mechanism — makes the mouse data more compelling than generic "improved cognition" in an animal model.

Exercise is the most established way to raise circulating klotho in humans. Multiple studies across different exercise modalities and populations have shown that physical activity, particularly aerobic exercise, raises serum klotho — sometimes measurably after a single session and more durably with sustained training.

That gives the klotho story an immediately practical edge even while the therapeutic question stays open: the most reliable lever on this longevity protein is the same one that supports nearly every system it touches. Direct klotho therapy remains genuinely research-stage, constrained by the difficulty of delivering a large protein and getting it across the blood-brain barrier, so for now klotho is best understood as a window into how systemic maintenance signaling shapes aging — and as one more mechanism through which exercise may earn its outsized place in healthspan.